|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
27,550,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NextCure is a clinical-stage biopharmaceutical company engaged on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Co.'s primary product candidate, NC318, is an immunomedicine against an immunomodulatory protein called Siglec-15. Co.'s second product candidate, NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Co.'s third product candidate, NC762, is an immunomedicine targeting a molecule called human B7 homolog 4 protein.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Heller Kevin N. |
Chief Medical Officer |
|
2020-07-14 |
4 |
OE |
$1.77 |
$48,195 |
D/D |
27,229 |
49,011 |
|
- |
|
Liu Linda |
SVP, Research |
|
2019-11-27 |
4 |
OE |
$0.48 |
$41,656 |
D/D |
55,234 |
55,234 |
|
- |
|
Powell Michael |
10% Owner |
|
2019-11-15 |
4 |
B |
$36.75 |
$5,512,500 |
D/D |
150,000 |
2,671,856 |
2.45 |
- |
|
Xu Stella |
Director |
|
2019-05-13 |
4 |
B |
$15.00 |
$1,875,000 |
I/I |
125,000 |
1,103,570 |
2.1 |
- |
|
Xu Stella |
Director |
|
2019-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
978,570 |
978,570 |
|
- |
|
Khuong Chau Quang |
Director |
|
2019-05-13 |
4 |
B |
$15.00 |
$5,250,000 |
I/I |
350,000 |
2,711,013 |
2.1 |
- |
|
Khuong Chau Quang |
Director |
|
2019-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
2,361,013 |
2,361,013 |
|
- |
|
Orbimed Capital Gp Vi Llc |
Director |
|
2019-05-13 |
4 |
B |
$15.00 |
$5,250,000 |
I/I |
350,000 |
2,711,013 |
2.25 |
- |
|
Orbimed Capital Gp Vi Llc |
Director |
|
2019-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
2,361,013 |
2,361,013 |
|
- |
|
Canaan Partners X Llc |
10% Owner |
|
2019-05-13 |
4 |
B |
$15.00 |
$750,000 |
D/D |
50,000 |
2,254,442 |
2.45 |
- |
|
Canaan Partners X Llc |
10% Owner |
|
2019-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,204,442 |
2,204,442 |
|
- |
|
Alexandria Venture Investments, Llc |
10% Owner |
|
2019-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
197,993 |
197,993 |
|
- |
|
Shannon Timothy M |
Director |
|
2019-05-13 |
4 |
B |
$15.00 |
$750,000 |
I/I |
50,000 |
2,254,442 |
2.1 |
- |
|
Shannon Timothy M |
Director |
|
2019-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
2,204,442 |
2,204,442 |
|
- |
|
Bingham James B. |
Chief Development OfficerOffic |
|
2019-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
87,131 |
|
- |
|
Heller Kevin N. |
Chief Medical OfficerOfficer |
|
2019-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,782 |
|
- |
|
Richman Michael |
President & CEOOfficer |
|
2019-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
385,869 |
|
- |
|
Kabakoff David S |
Director |
|
2019-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
62,237 |
|
- |
|
Langermann Sol |
Chief Scientific OfficerOffice |
|
2019-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
37,342 |
|
- |
|
19 Records found
|
1
|
Page 1 of 1 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|